Erlotinib intermediates manufacturer
CAS No.:763113-22-0
Other Names:AZD2281
MF:C24H23FN4O3
Place of Origin:CHINA
Type:Antineoplastic Agents
Grade Standard:Medicine Grade
Purity:99.0%MIN
Appearance:White to off-white powder
Melting point:209~212°C
Loss on Drying:0.5%MAX
Residue on ignition:0.5%MAX
Heavy metal:20ppm Max
Chloride:0.03% MAX
Packaging & Delivery
l Packaging Details
OPTION TO CUSTOMER
Port: any port in China
Olaparib
1.Specification:
|
Product name |
Olaparib |
|
CAS |
763113-22-0 |
|
Package |
Option to customer |
|
Stock |
Fresh |
|
Molecular Structure |
|
|
Molecular Formula |
C24H23FN4O3 |
|
Molecular Weight |
434.46 |
2.Detailed Product Description: (COA)
|
Items |
The Standard Result |
|
Appearance |
White to off-white powder |
|
Identification |
H-NMR, MS |
|
Melting point |
209~212°C |
|
Loss on Drying |
£0.5% |
|
Residue on ignition |
£0.5% |
|
Heavy metal |
£20ppm |
|
Chloride |
£0.03% |
|
Related Impurity by HPLC |
Total impurity ≤1.0% Single impurity≤0.5% |
|
Purity (HPLC) |
³99.0% |
3.Function and usage
Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed by KuDOS Pharmaceuticals and later by AstraZeneca. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers. In December 2014, olaparib was approved for use as a single agent by the EMA and the FDA. The FDA approval is in for germline BRCA mutated (gBRCAm) advanced ovarian cancer that has received three or more prior lines of chemotherapy.
4.Payment:
Terms:100%Pay in advanced, T/T, Western Union or PayPal are OK or Kindly indicate
5.Delivery:
In about 15 working days after the receipt of payment, we will follow up the delivery until you receive it.(Shipping : TNT,Fedex,DHL,USP,EMS and so on)
6. Packaging:
Drum&plastic bags, Aluminum foiled bag, Zip lock bags
